Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Completed 3

Sponsor Class

NIH 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 8Breast 4Tumor-Agnostic 3Thoracic 3Other hematologic neoplasm 3Lymphoid 3Gynecologic 3Head & Neck 2Genitourinary 2Dermatologic 2Other solid neoplasm 1NET 1Endocrine 1

Conditions

Lymphoma, Large B-Cell, Diffuse 2Leukemia, Lymphocytic, Chronic, B-Cell 2Waldenstrom Macroglobulinemia 1Sezary Syndrome 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Mycosis Fungoides 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Follicular 1Lymphoma, Extranodal NK-T-Cell 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Large Granular Lymphocytic 1Leukemia, Hairy Cell 1Intraocular Lymphoma 1Immunoblastic Lymphadenopathy 1Hodgkin Disease 1

Interventions

Rituximab 530Cyclophosphamide 425Vincristine 219Doxorubicin 192fludarabine phosphate 177Etoposide 167Prednisone 166fludarabine 162Methotrexate 162Cytarabine 157Filgrastim 125Dexamethasone 123Lenalidomide 121Granulocyte Colony-Stimulating Factor 116Whole-Body Irradiation 107Mycophenolic Acid 99ibrutinib 97Bendamustine Hydrochloride 91Tacrolimus 88Melphalan 85Calcium Dobesilate 82Peripheral Blood Stem Cell Transplantation 80Bortezomib 80Busulfan 78obinutuzumab 64ofatumumab 59Radiotherapy 57Cyclosporine 57Antilymphocyte Serum 55Brentuximab Vedotin 54

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has results × MK 2206 × Lymphoid × Clear all
NCT01258998 2020-11-04

Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma

National Cancer Institute (NCI)

Phase 2 Completed
60 enrolled 8 charts
DermatologicLymphoidOther hematologic neoplasm

Hodgkin Disease, Immunoblastic Lymphadenopathy, Leukemia, Hairy Cell, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Mycosis Fungoides, Sezary Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Leukemia, Large Granular Lymphocytic, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell, Intraocular Lymphoma

NCT01481129 2017-09-28

Akt Inhibitor MK2206 in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

National Cancer Institute (NCI)

Phase 2 Completed
22 enrolled 9 charts
Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT01369849 2017-09-15

Akt Inhibitor MK2206, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

National Cancer Institute (NCI)

Phase 1/2 Completed
15 enrolled 13 charts
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡